Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs Bristol Myers Squibb announced positive topline results from the planned interim analysis of the ACTION-1 trial…
Transcripta Bio & Synfini Collaborate to Identify a Lead Candidate Against a Key Driver of Huntington’s Disease Progression in a Matter of Weeks Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an…
Mitsui Chemicals Launches InnoCell™ P-Type High Oxygen-Permeable Culture Plates to Accelerate Organoid-Based Drug Discovery Mitsui Chemicals, Inc. has launched InnoCell™ P-Type, a new adherent cell culture plate in its InnoCell™ series of cell culture ware, as of October 1, 2026.…
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway Summit Therapeutics Inc. announced a clinical trial collaboration agreement with Daiichi Sankyo and AstraZeneca to evaluate ivonescimab, a novel, potential…
Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer Vividion Therapeutics, Inc. a clinical-stage biopharmaceutical company and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of the…
The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women The Estée Lauder Companies announced a new five-year commitment to the Breast Cancer Research Foundation to establish the Global…
Vyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND Application Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced that…
IMCD to showcase formulation concepts and sensory experience at In-Cosmetics Latin America 2026 IMCD Group a leading global partner for the distribution and formulation of speciality chemicals and ingredients, will be exhibiting at In-Cosmetics Latin America 2026, on 23 and…
The Gabrail Cancer Center Undertakes Investigator-Initiated Study Evaluating the T-Cell Engager Elranatamab in Combination with Starton Therapeutics’ Controlled Low-Dose Lenalidomide The Gabrail Cancer and Research Center, a PhaseWell Research site, announced that Nashat Gabrail, M.D., has received notification from the…
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans Hyperfine, Inc. the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for…
American Chemical Society Names Syngenta’s Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals Camilla Corsi, Head of Crop Protection Research & Development at Syngenta, is the winner of the prestigious 2026 American Chemical Society (ACS)…
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status Gilead Sciences, Inc. announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult…